Non-invasive assessment of HER2 expression in patients with urothelial carcinoma using [68Ga]Ga-HER2 affibody PET/CT imaging: preliminary clinical findings
European Journal of Nuclear Medicine and Molecular Imaging · 2025-07 · 52 (8) · 2782-2791
DOI: 10.1007/s00259-025-07142-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 14.02.2025. Verfasst von Sijuan Zou und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Tongji hospital, Tongji medical college, Huazhong University of Science and Technology, Wuhan, 430030, Hubei Province…. Hauptthemen laut MEDLINE: Gene Expression Regulation, Neoplastic, Positron Emission Tomography Computed Tomography, Erb-b2 Receptor Tyrosine Kinases, Urologic Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
PURPOSE: Recently, novel human epidermal growth factor receptor 2 antibody-drug conjugate therapies have shown remarkable efficacy in treating urothelial carcinoma, highlighting the growing need for comprehensive assessment of HER2 expression in tumors to identify patients who could benefit. However, non-invasive methods for assessing HER2 status in patients with urothelial carcinoma remain limited. This study aimed to preliminarily evaluate the clinical potential of [68Ga]Ga-HER2 affibody PET/CT for non-invasive assessment of HER2 expression in patients with urothelial carcinoma. MATERIALS AND METHODS: A cohort of 25 patients with urothelial carcinoma was retrospectively included from a prospective parent study (NCT05535621), and sequential PET/CT using [68Ga]Ga-HER2 affibody and [18 F] FDG was performed. HER2 status was assessed through pathological evaluation using immunohistochemistry, with scoring categories of 0, 1+, 2+, and 3+. Lesion uptake on PET/CT was quantified using the maximum standardized uptake value (SUVmax). Comparisons of SUVmax between primary tumor groups with different HER2 expression levels (HER2-positive IHC 2+, 3 + vs. HER2-negative IHC 0, 1+, and HER2-expression IHC 1+, 2+, 3 + vs. HER2-zero IHC 0) were conducted using nonparametric statistical tests. Additionally, the correlation between tumor SUVmax and HER2 expression status was analyzed, and the HER2 PET metastasis-positive rate at the patient level in metastatic urothelial carcinoma was determined. RESULTS: Twenty-five patients (mean age, 65.6 years ± 11.1 [SD]); 18 men) with urothelial carcinoma were enrolled. HER2 status in primary tumor was confirmed IHC 0 in four cases, IHC 1 + in three cases, IHC 2 + in six cases, IHC 3 + in three cases, and unknown in seven cases with potential HER2 expression. One patient with ureterostomy recurrence had HER2 IHC 1+, while another case was confirmed IHC 2 + through biopsy of metastatic lesion. In 16 participants with urothelial carcinoma, the SUVmax of HER2-positive primary tumors (IHC 2 + and 3+, n = 9) were higher than those of HER2-negative tumors (IHC 0 and 1+, n = 7) (median SUVmax, 7.07 ± 0.69 vs. 4.48 ± 1.14, p = 0.042) on [68Ga]Ga-HER2 affibody PET/CT. Additionally, a similar difference was observed between the HER2-expression group (IHC 1+, 2+, 3+, n = 12) and the HER2-zero group (IHC 0, n = 4) (median SUVmax, 6.97 ± 0.70 vs. 2.85 ± 0.19, p = 0.001). Primary tumors in 13 of the 16 patients were semi-quantitatively measurable on FDG PET/CT imaging, with no significant difference in FDG SUVmax between the HER2-positive and HER2-negative group (7 HER2-positive vs. 6 HER2-negative; median SUVmax: 19.56 ± 5.02 vs. 19.10 ± 3.13, p = 0.731). Spearman correlation analysis revealed a positive correlation between HER2 PET SUVmax and HER2 expression levels in primary urothelial carcinoma (R = 0.727, p = 0.001), whereas no correlation was found between FDG SUVmax and HER2 expression levels (p > 0.05). In 14 patients with metastatic urothelial carcinoma, HER2 affibody PET/CT identified HER2 PET-positive metastatic lesions with a 92.86% positivity rate (13/14). CONCLUSION: [68Ga]Ga-HER2 affibody PET/CT is a valuable non-invasive method for evaluating HER2 expression in patients with urothelial carcinoma. TRIAL REGISTRATION: NCT05535621. Registered 18 December 2021.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Tongji hospital, Tongji medical college, Huazhong University of Science and Technology, Wuhan, 430030, Hubei Province, China.
- Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Ministry of Health, Jiangsu Institute of Nuclear Medicine, Wuxi, China.
- Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Ministry of Health, Jiangsu Institute of Nuclear Medicine, Wuxi, China. yangmin@jsinm.org.
- Department of Nuclear Medicine, Tongji hospital, Tongji medical college, Huazhong University of Science and Technology, Wuhan, 430030, Hubei Province, China. evazhu@vip.sina.com.
ORCID-Profile: Xiaohua Zhu
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zou, S., Liu, Z., Zhou, J., Song, S., Wang, D., Zhu, D., Cheng, S., Cheng, Z., Zhu, Y., Yu, T., Pan, D., Yang, M., & Zhu, X. (2025). Non-invasive assessment of HER2 expression in patients with urothelial carcinoma using [68Ga]Ga-HER2 affibody PET/CT imaging: preliminary clinical findings. European Journal of Nuclear Medicine and Molecular Imaging, 52(8), 2782-2791. https://doi.org/10.1007/s00259-025-07142-0
Vancouver
Zou S, Liu Z, Zhou J, Song S, Wang D, Zhu D, et al. Non-invasive assessment of HER2 expression in patients with urothelial carcinoma using [68Ga]Ga-HER2 affibody PET/CT imaging: preliminary clinical findings. European Journal of Nuclear Medicine and Molecular Imaging. 2025;52(8):2782-2791. doi:10.1007/s00259-025-07142-0
BibTeX
@article{Zou2025,
author = {Zou, Sijuan and Liu, Zheng and Zhou, Jianyuan and Song, Shuang and Wang, Dongdong and Zhu, Dongling and Cheng, Siyuan and Cheng, Zhaoting and Zhu, Yuankai and Yu, Tianci and Pan, Donghui and Yang, Min and Zhu, Xiaohua},
title = {Non-invasive assessment of HER2 expression in patients with urothelial carcinoma using [68Ga]Ga-HER2 affibody PET/CT imaging: preliminary clinical findings},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2025},
volume = {52},
number = {8},
pages = {2782--2791},
doi = {10.1007/s00259-025-07142-0}
}
EUVIMED